Close Menu

NEW YORK (360Dx) – When Owlstone Medical today announced a collaboration with Renji Hospital to conduct a clinical study into the early detection of lung cancer in China, the deal became one among several clinical studies in which the firm is participating to validate its breath biopsy platform.

Although financial and other terms of the deal were not disclosed, the partners said that they will establish a breath biopsy laboratory in China to support the study.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.